Federal lawyers asked a judge on Friday to let federal health officials decide how to give 340B hospitals relief for illegal Medicare Part B drug payment cuts since 2018.
In papers filed in U.S. District Court for the District of Columbia
…
Year: 2022
The U.S. Senate Appropriations Committee wants federal healthcare officials to tell it what they have done about drug manufacturers’ denials of 340B pricing when covered entities use contract pharmacies.
The committee included the directive to the U.S. Health Resources and
…
A federal jury in Illinois last week ordered drug manufacturer Lilly to pay more than $61 million in damages for misstating its average manufacturer prices (AMP) and underpaying Medicaid drug rebates.
AMP is a key component used to determine 340B
…
The U.S. Health and Human Services Department (HHS) asked a federal district judge late last week not to make it rush its response to hospitals’ request for an immediate halt to a nearly 30% Medicare Part B payment cut in
…
The U.S. Health Resources and Services Administration (HRSA) is letting eligible healthcare providers in flood-devastated Kentucky enroll in the 340B program immediately instead of making them wait until the next quarterly enrollment period in October.
U.S. Health and Human Services
…
The U.S. Senate on Sunday rejected a Republican amendment to Democratic drug pricing and climate change legislation that would have required federally qualified health centers to make insulin and injectable epinephrine available to patients at or below 340B price.
But
…
The U.S. Senate on Sunday passed historic legislation to let Medicare negotiate the prices of a small number of costly medicines and require drug manufacturers to pay Medicare rebates when prices paid by Medicare rise faster than inflation.
Language in
…
CivicaScript, a unit of hospital-owned nonprofit drug company Civica Rx, has launched its first low-cost generic drug available in the outpatient pharmacy setting: abiraterone acetate (brand name Zytiga) used to treat metastatic prostate cancer. The company will sell abiraterone to
…
Drug manufacturer Boehringer Ingelheim (BI) said on Friday that health centers will be subject to its limits on 340B pricing involving contract pharmacies starting Sept. 1. The restrictions previously applied to hospitals only. “At this time, for all other federal
…